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Purpose of the study
Antiretroviral (ARV) regimens may be statistically non-
inferior in clinical trials, but have very different economic
outcomes due to differences in costs and adverse event
profiles. Given the heavy cost burden of HIV disease, it is
important to consider economic issues when selecting an
ARV regimen. This study examines the cost and conse-
quences of initiating an ARV regimen including LPV/r or
EFV, using data from a recent clinical trial in a previously
published model of HIV-disease.
Methods
We populated the Markov model of HIV-disease with data
from A5142 study to estimate the economic outcomes of
starting ARV therapy with a PI-containing regimen as
compared to an NNRTI-containing regimen, given their
virologic and immunologic efficacy and effects on choles-
terol and lipoatrophy. CNS toxicities and GI tolerability
were not included in the model because of their transient
nature, low cost remedies and lack of economic impact.
CD4+ T-cell counts and the HIV-1 RNA (viral load) values
from the study, were used to assign a specific health state
(HS) to each patient for each quarter-year. The resulting
frequencies used as "raw" data directly into the model
obviate the reliance on statistical tests, and allow the
model to reflect actual patient behavior in the clinical
trial. An HS just below the last observed HS was used to
replace a missing value.
Summary of results
The modeled estimates (undiscounted) for the LPV/r-
based regimen results in 1.41 quality-adjusted life months
(QALMs) gained over a lifetime compared to the EFV-
based regimen. The LPV/r-based regimen incurs $7,458
(1.8%) greater cost over a lifetime due to differences in
drug costs and survival. The incremental cost-effectiveness
ratio using the discounted cost and QALYs is $88,829/
QALY. Most of the higher costs accrue before the 7th year
of treatment and are offset by subsequent savings. The
estimates are highly sensitive to the effect of lipoatrophy
on quality of life, but not to the effect of cholesterol levels.
Conclusion
Initiating an LPV/r-containing regimen on ARV-naive
patients appears cost-effective compared to an EFV-based
regimen, when the cost and consequences of lipoatrophy
are included.
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